Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397] by Christ-Crain, Mirjam et al.
Open Access
Available online http://ccforum.com/content/10/3/R96
Page 1 of 8
(page number not for citation purposes)
Vol 10 No 3 Research
Pro-adrenomedullin to predict severity and outcome in 
community-acquired pneumonia [ISRCTN04176397]
Mirjam Christ-Crain1, Nils G Morgenthaler2, Daiana Stolz3, Christian Müller1, Roland Bingisser1, 
Stephan Harbarth4, Michael Tamm3, Joachim Struck2, Andreas Bergmann2 and Beat Müller1
1Department of Internal Medicine, University Hospital Basel, Switzerland
2Research Department, Brahms AG, Hennigsdorf, Germany
3Department of Pneumology, University Hospital Basel, Switzerland
4Division of Hospital Epidemiology, Geneva University Hospitals
Corresponding author: Mirjam Christ-Crain, christmj@bluewin.ch
Received: 25 Apr 2006 Accepted: 22 May 2006 Published: 28 Jun 2006
Critical Care 2006, 10:R96 (doi:10.1186/cc4955)
This article is online at: http://ccforum.com/content/10/3/R96
© 2006 Christ-Crain et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Pro-adrenomedullin (proADM) is helpful for
individual risk assessment and outcome prediction in sepsis. A
major cause of sepsis is community-acquired pneumonia (CAP).
The aim of this study was to investigate the value of proADM
levels for severity assessment and outcome prediction in CAP.
Methods Data from 302 patients admitted to the emergency
department with CAP were included in a prospective
observational study. Procalcitonin, C-reactive protein levels,
leukocyte count, clinical variables and the pneumonia severity
index (PSI) were measured. ProADM levels were measured with
a new sandwich immunoassay for mid regional ProADM (MR-
proADM, Brahms AG, Hennigsdorf/Berlin, Germany).
Results ProADM levels, in contrast to C-reactive protein and
leukocyte count, increased with increasing severity of CAP,
classified according to the PSI score (ANOVA, p < 0.001). In
patients who died during follow-up, proADM levels on admission
were significantly higher compared to levels in survivors (2.1
(1.5 to 3.0) versus 1.0 (0.6 to 1.6) nmol/l, p < 0.001). In a
receiver operating characteristic (ROC) analysis for survival, the
area under the ROC curve (AUC) for proADM was 0.76 (95%
confidence interval (CI) 0.71–0.81), which was significantly
higher compared to procalcitonin (p  = 0.004), C-reactive
protein (p < 0.001) and total leukocyte count (p = 0.001) and
similar to the AUC of the PSI (0.73, p = 0.54). A clinical model
including the PSI and proADM increased the prognostic
accuracy to predict failure compared to a model relying on the
PSI alone (AUC, 0.77 (0.70 to 0.84), p = 0.03).
Conclusion ProADM, as a novel biomarker, is a useful tool for
the risk stratification of patients with CAP.
Introduction
Adrenomedullin (ADM) is one of the most potent vasodilating
agents and has additional immune modulating, metabolic
properties [1-4]. ADM also has a bactericidal activity that is
further enhanced by modulation of complement activity and
regulation [5-7]. Thus, it is not surprising that serum ADM lev-
els are increased in sepsis [8]. The reliable measurement of
ADM is challenging, since it is rapidly cleared from the circula-
tion [1,2,9,10]. The more stable mid-region fragment of pro-
adrenomedullin (proADM) directly reflects levels of the rapidly
degraded active peptide ADM [11]. Recently, proADM has
been shown to be a helpful prognostic tool for individual risk
assessment in sepsis [12].
A main cause of sepsis is community-acquired pneumonia
(CAP), which is the major infection-related cause of death in
developed countries [13,14]. In the assessment and manage-
ment of CAP, estimation of the disease severity is crucial for
guiding therapeutic options such as the need for hospital or
intensive care admission, the intensity of work-up, the choice
and route of antimicrobial agents and the suitability for dis-
charge [15,16].
The pneumonia severity index (PSI) is a widely accepted and
validated severity scoring system that assesses the risk of
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mortality for pneumonia patients in a two-step algorithm [17].
However, its complexity is high, jeopardizing its dissemination
and implementation, especially in everyday practice. There-
fore, the CURB-65 score has been proposed as a simpler
alternative [18]. Additionally, various easy to determine surro-
gate biomarkers have been proposed to predict disease sever-
ity in CAP patients, thereby aiming to complement the PSI
score [19-21].
In this study, we investigated the prognostic value of proADM
compared to other biomarkers (such as; procalcitonin, C-reac-
tive protein (CRP) and leukocyte count), alone and in combi-
nation with the PSI in a well-defined cohort of 302 consecutive
patients with CAP [22].
Materials and methods
Setting and study population
Data from 302 patients admitted to the emergency depart-
ment with CAP were analyzed. The primary objective of the
study was to evaluate antibiotic duration by procalcitonin guid-
ance compared to standard recommended guidelines [22]. A
predefined secondary endpoint was the assessment of prog-
nostic factors and biomarkers in CAP.
Consecutive patients with CAP admitted from November
2003 through February 2005 to the University Hospital Basel,
Switzerland, a 950 bed tertiary care hospital, were included.
Patients had to be >18 years of age with a suspected CAP as
principal diagnosis on admission. Excluded were patients with
cystic fibrosis or active pulmonary tuberculosis, hospital-
acquired pneumonia and severely immunocompromised
patients. Patients were examined on admission to the emer-
gency department by a resident supervised by a board-certi-
fied specialist in internal medicine. Baseline assessment
included clinical data and vital signs, comorbid conditions, and
routine blood tests. Functional status of the patients was
assessed using a visual analogue scale, ranging from 0 (feel-
ing extremely ill) to 100 (feeling completely healthy), and by a
quality of life questionnaire for patients with respiratory ill-
nesses [23].
CAP was defined by the presence of one or several of the fol-
lowing recently acquired respiratory signs or symptoms:
cough, sputum production, dyspnea, core body temperature
>38.0°C, auscultatory findings of abnormal breath sounds and
rales, leukocyte count >10 or <4 × 109 cells l-1 and an infiltrate
on chest radiograph [14]. The PSI was calculated as
described elsewhere [17]. Chest radiographs were screened
by the physician in charge and reviewed by a senior radiolo-
gist, unaware of clinical and laboratory findings.
The study was approved by the local ethics committee for
human studies and written informed consent was obtained
from all patients.
Outcome
All patients were followed-up for a mean duration of 6.9 ± 1.9
weeks [22]. At the follow-up visit, outcome was evaluated by
clinical, laboratory, radiographic and microbiological criteria.
Cure was defined as resolution of clinical, laboratory and radi-
ographic signs of CAP. Improvement was defined as reduction
of clinical signs and symptoms, improvement of laboratory
findings (for example; CRP, procalcitonin and leukocyte count)
and a reduction in the number or intensity of radiographic
signs of CAP. Treatment success represented the sum of the
rates for cure and improvement. Treatment failure included
death, recurrence or persistence of clinical, laboratory and
radiological signs of CAP at follow-up.
Patients who survived until follow-up were counted as survi-
vors whereas patients who died within the follow-up period
were counted as non-survivors.
Microbial investigations
The laboratory workup for the patients with CAP has been pre-
viously described [22]. Briefly, it included sputum samples
from Gram stain and culture, two blood samples for culture
and a urine sample for detection of Legionella pneumophila.
Measurement of proADM and other laboratory 
parameters
ProADM was detected in EDTA plasma of all patients with a
new sandwich immunoassay (MR-proADM, BRAHMS AG,
Hennigsdorf, Berlin, Germany), as described [24]. The assay
(normal reference range 0.33 ± 0.7 nmol/l) has an analytical
detection limit of 0.08 nmol/l and a functional assay sensitivity
of 0.12 nmol/l. Procalcitonin was measured by a time-resolved
amplified cryptate emission (TRACE) technology assay (Kryp-
tor® PCT, Brahms AG, Hennigsdorf, Berlin, Germany) with a
functional assay sensitivity of 0.06 µg/l. CRP was measured
with an enzyme immunoassay (EMIT, Merck Diagnostica,
Zurich, Switzerland).
Statistical analysis
Discrete variables are expressed as counts (percentage) and
continuous variables as means ± standard deviation (SD) or
median and interquartile range in parentheses unless stated
otherwise. Frequency comparison was done by chi-square
test. Two-group comparison of normally distributed data was
performed by Students t test. For multigroup comparisons,
one-way analysis of variance with least square difference for
post hoc comparison was applied. For data not normally dis-
tributed, the Mann-Whitney U test was used if only two groups
were compared and the Kruskal-Wallis one-way analysis of
variance was used if more than two groups were being com-
pared. Receiver-operating-characteristics were calculated
using STATA (version 9, Statacorp, Texas, USA). Thereby,
outcomes were either survival until follow-up, or failure includ-
ing death until follow-up, respectively. To estimate the poten-
tial clinical relevance of proADM measurements, we usedAvailable online http://ccforum.com/content/10/3/R96
Page 3 of 8
(page number not for citation purposes)
likelihood-ratio tests to determine whether logistic regression
models that included measurements of proADM and the PSI
provided a significant better fit than did logistic regression
models limited to the PSI alone [25]. Correlation analyses
were performed by using Spearman rank correlation. Levels
that were non-detectable were assigned a value equal to the
lower limit of detection for the assay. All testing was two-tailed
and p values less than 0.05 were considered to indicate sta-
tistical significance.
Results
Patients
Detailed baseline characteristics of the study population are
summarized in Table 1. The mean age of the 302 patients was
69.6 ± 17.0 years. Of the patients, 73 (24.2%) were smokers
and 61 (20.2%) were pretreated with antibiotics. Fever >38°C
was present in 60% of CAP patients and the typical triad of
cough, fever and dyspnea, as reported by the patient, in 58%
of cases. Overall, 87.5% of patients had relevant co-morbidi-
ties.
The mean PSI of all patients was 99.4 ± 35.3 points: 22
patients (7.3%) had a PSI class I; 41 (13.6%) a PSI class II;
57 (18.9%) a PSI class III, 130 (43.0%) a PSI class IV; and 52
(17.2%) a PSI class V. 271 patients (89.7%) were hospital-
ized for more than one night.
A microbiological diagnosis was achieved in 80 (26.5%)
patients (in respiratory secretions in 51 (16.9%) and in blood
cultures in 29 (9.6%) patients). The most frequently isolated
microorganism was Streptococcus pneumoniae (detected in
42 patients, 14%), followed by Pseudomonas aeruginosa (10
patients, 3%), Haemophilus influenzae (7 patients, 2%), Kleb-
siella pneumoniae (5 patients, 2%), and L. pneumophila (5
patients, 2%).
ProADM levels and severity of CAP
ProADM levels increased with increasing severity of CAP,
classified according to the PSI score (p < 0.001). This gradual
increase was also present but less pronounced for procalci-
tonin levels (p < 0.001), and not significant for CRP (p = 0.24),
total leukocyte count (p = 0.13) (Figure 1), body temperature
(p = 0.30) and the visual analogue scale (p = 0.39).
Figure 1
Pro-adrenomedullin (proADM), procalcitonin (proCT), C-reactive protein (CRP) levels and leukocyte count in different severities of community- acquired pneumonia Pro-adrenomedullin (proADM), procalcitonin (proCT), C-reactive protein (CRP) levels and leukocyte count in different severities of community-
acquired pneumonia. Data are shown as means ± standard error of the mean, with scatterplots representing all values. PSI, pneumonia severity 
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ProADM levels were significantly higher on admission (median
(interquartile range) 1.1 (0.7 to 1.9) nmol/l compared to levels
at follow-up after 6.9 ± 1.9 weeks (0.7 (0.5 to 1.0) nmol/l, p <
0.001). ProADM levels correlated with other biomarkers of
infection, that is, procalcitonin (r = 0.51, p < 0.001), and to a
lesser degree with CRP (r = 0.16, p < 0.01), and total leuko-
cyte count (r = 0.23, p < 0.001). There was a significant cor-
relation with the PSI score (r = 0.64, p < 0.001) and with
serum creatinine levels (r = 0.60, p < 0.001).
ProADM levels were significantly higher in patients with multi-
lobar pneumonia (1.4 (0.9 to 2.2) nmol/l) compared to patients
with unilateral pneumonia (1.0 (0.6 to 1.8) nmol/l, p = 0.01).
The respective values for procalcitonin were 0.8 (0.3 to 3.9)
Figure 2
Receiver operator curve analysis of different laboratory parameters predicting failure after treatment of community-acquired pneumonia Receiver operator curve analysis of different laboratory parameters predicting failure after treatment of community-acquired pneumonia. Data on 
admission are shown. Upper panel: receiver operator curve (ROC) plot analysis of different parameters (i.e., pro-adrenomedullin (proADM), procalci-
tonin (proCT), C-reactive protein (CRP), leukocyte count (Lc count) and the pneumonia severity index (PSI)). Lower panel: ROC plot analysis of a 
combined model of proADM and the PSI compared to proADM and the PSI alone.Available online http://ccforum.com/content/10/3/R96
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versus 0.5 (0.2 to 1.6), p = 0.02. CRP and leukocyte count
were not significantly different between the two groups (data
not shown). Patients with positive blood cultures had signifi-
cantly higher proADM levels compared to patients with nega-
tive blood cultures (2.4 (1.6 to 3.0) versus 1.0 (0.6 to 1.7)
nmol/l, p < 0.001). The respective values were: for procalci-
tonin, 8.0 (2.1 to 20.2) versus 0.4 (0.2 to 1.3), p < 0.001; for
CRP, 197.5 (119.7 to 268.9) versus 122.7 (62.6 to 203.5), p
= 0.002; and for leukocyte count, 17.1 ± 8.9 versus 13.2 ±
6.2, p = 0.004.
Patients who were hospitalized for more than one night had
significantly higher proADM levels compared to patients who
were not hospitalized or were hospitalized only for one night
(1.1 (0.7 to 1.9) versus 0.73 (0.45 to 1.1) nmol/l, p = 0.001).
The respective values were: for procalcitonin, 0.5 (0.2 to 2.6)
versus 0.2 (0.1 to 0.77) µg/l, p = 0.002; for CRP (132.0 (65.5
to 211.8) versus 84.6 (40.0 to 190.0) mg/L, p = 0.052; and
for leukocyte count, 13.4 ± 6.5 versus 14.5 ± 7.8 × 109/l, p =
0.76.
ProADM levels as a prognostic marker for outcome
At follow-up, 251 patients had a successful outcome (213
were cured, 38 improved). Failure at follow-up was noted in 51
patients (including death in 38 patients). Thus, the mortality
rate was 12.6%.
In patients who died during follow-up, proADM levels on
admission were significantly higher compared to levels in sur-
vivors (2.1 (1.5 to 3.0) versus 1.0 (0.6 to 1.6) nmol/l, p <
0.001). The respective values were: for procalcitonin, 0.7 (0.4
to 3.0) versus 0.4 (0.1 to 0.9) µg/l, p = 0.03); for CRP, 153
(93 to 204) versus 126.3 (63 to 211) mg/l, p = 0.57; and for
total leukocyte count, 14.8 ± 8.2 versus 13.4 ± 6.4 × 109/l, p
= 0.24.
In a receiver operating characteristic (ROC) analysis where
sensitivity was calculated with those patients who died until
follow-up (n = 38) and specificity was assessed with those
patients who survived until follow-up (n = 264), the area under
the ROC curve (AUC) for proADM was 0.76, which was sig-
nificantly better compared to procalcitonin (p = 0.004), CRP
(p < 0.001) and total leukocyte count (p = 0.001) and similar
to the AUC of the PSI (p = 0.54). The optimal prognostic accu-
racy for proADM was 1.8 nmol/l. With this cut-off, the sensitiv-
ity to correctly predict mortality until follow-up was 80%, the
specificity 72%, the positive likelihood ratio (LHR+) 2.9 and
the negative likelihood ratio (LHR-) 0.28. For the PSI with an
optimal threshold of 101 points, the sensitivity was 58%, the
specificity 84%, the LHR+ 3.7 and the LHR- 0.5.
To predict failure including death, the AUC for proADM was
0.73 (0.68 to 0.78), which was significantly higher compared
to CRP (AUC 0.59 (0.53 to 0.65), p = 0.02), and leukocyte
count (0.55 (0.49 to 0.61), p = 0.002) and similar to the PSI
Table 1
Baseline characteristics of the 302 patients
Characteristic
Age, years 69.6 ± 17.0a
Male sex, no. (%) 187 (61.9)
Smoking status
Current smoker, no. (%) 73 (24.2)
Pack-years for smokers 40.1 ± 24.2a
Antibiotic pretreatment (%) 61 (20.2)
Coexisting illnesses, no. (%)
Coronary artery disease 97 (32.1)
Hypertensive heart disease 78 (25.8)
Congestive heart failure 16 (5.3)
Peripheral vascular disease 20 (6.6)
Cerebrovascular disease 16 (5.3)
Renal dysfunction 81 (26.8)
Liver disease 31 (10.3)
Diabetes mellitus 61 (20.2)
Chronic obstructive pulmonary 
disease
76 (25.2)
Neoplastic disease 48 (15.9)
History, no. (%)
Cough 270 (89.4)
Sputum 221 (73.2)
Dyspnea 229 (75.8)
Examination, no. (%)
Rales 271 (89.7)
Laboratory findings
CRP (mg/l), median (IQ range) 129.7 [65–211]
Procalcitonin (µg/l), median (IQ range) 0.5 [0.2–2.2]
Leukocyte count (× 109) 13.6 ± 6.7a
proADM (pmol/l), median (IQ range) 1.1 [0.6–1.9]
Radiographic findings, no. (%)
Pleural effusion 37 (12.3)
Multilobar CAP 53 (17.5)
PSI points 99.4 ± 35.3a
PSI class, no. (%)
I, II and III 120 (39.7)
IV 130 (43)
V5 2  ( 1 7 )
aValues are means ± standard deviation unless stated otherwise. 
Because of rounding, percentages may not sum to 100. ADM, 
adrenomedullin; CRP, C-reactive protein; PSI = pneumonia severity 
index.Critical Care    Vol 10 No 3    Christ-Crain et al.
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(AUC 0.73 (0.67 to 0.78), p = 0.93) and procalcitonin (0.65
(0.59 to 0.70), p = 0.11) (Figure 2, upper panel).
Forty-one patients needed to be transferred to the ICU during
hospitalization. To predict the need for ICU stay, proADM had
an AUC of 0.65 (0.59 to 0.70), which was similar to the AUCs
of CRP, leukocyte count, procalcitonin and the PSI (data not
shown).
As a measure of clinical usefulness, we evaluated the com-
bined role of proADM levels and the PSI as predictors of fail-
ure. ProADM could significantly improve the prognostic
accuracy of the PSI to predict failure (AUC for the combined
model, 0.77 (0.70 to 0.84), p = 0.03, compared to the PSI
alone) (Figure 2, lower panel).
Discussion
ProADM levels on admission predict the severity and outcome
of CAP with a similar prognostic accuracy as the PSI and a
higher prognostic accuracy compared to commonly measured
clinical and laboratory parameters.
A key decision for a clinician is whether to admit a patient with
CAP [26]. This decision is complex and depends on many var-
iables, including estimates of the severity of illness. It often
relies on the clinician's judgment; however, the interpretation
of clinical signs and symptoms lacks standardization and vali-
dation and is prone to inter-observer variability [27]. In addi-
tion, physicians continue to be conservative and commonly
overestimate the risk of death in patients with CAP [28]. Thus,
prognostic scoring rules have been developed to predict
severity of CAP and outcome, with the PSI being a well-vali-
dated prognostic classification score [17,18,29-31]. Limita-
tions of the PSI include a potential overemphasis on age and
the fact that for clinical ease, the PSI dichotomizes continuous
values such as heart rate or oxygen saturation into normal and
abnormal values. The intra-observer variation of the PSI is
reported to be around 10%, with most patients misclassified
in high-risk classes IV and V [32]. The PSI is better validated
for assessing patients with a low mortality risk who may be
suitable for home management rather than for those with
severe CAP at the time of hospital admission [18]. Some clini-
cians argue that the score is not practical for routine patient
management, restricting its widespread adoption. The CURB-
65 score has been proposed as a simpler alternative; how-
ever, it had not been as extensively validated [18]. The Ameri-
can Thoracic Society (ATS) guidelines do not offer any
algorithm for the clinical assessment of disease severity
[14,33]. There are also no universally accepted criteria for
severe CAP requiring admission to an ICU.
In this context, there is need for readily measurable biomarkers
predicting the severity level and outcome of CAP. ProADM lev-
els on admission had a similar prognostic accuracy as the PSI
and, based on our data, represent an additional and easy-to-
determine prognostic tool. It is advisable to support the com-
plex task of prognostic assessment and treatment decisions
with several clinical and laboratory parameters that may mirror
different physiological aspects. ProADM might also act as an
additional margin of safety to guide management decisions,
since adding proADM to the PSI increased predictive
accuracy.
CRP was put forward as a useful marker for predicting disease
severity in patients with pneumonia [19]. In contrast, in our
study, CRP could not differentiate between different severities
of CAP, as defined by the PSI. It must be taken into account
that CRP is a rather non-specific marker of acute-phase inflam-
mation and, therefore, is subject to the influence of many other
factors. IL-6, a key stimulator of hepatic CRP release, has also
been investigated for the determination of the severity of CAP
[34]. Measuring of plasma cytokines like IL-6, however, is cum-
bersome, partly because of the short plasma half-life and the
presence of blocking factors [35]. Most recently, D-Dimers
have been suggested as a prognostic parameter in CAP [21].
As a limitation of our study, we did not measure D-Dimer levels
and can not show comparative results. Procalcitonin has been
proposed as a marker of disease severity by our group and
others [20,22]. However, based on our results, proADM is a
prognostic marker and predicts the severity of disease,
whereas procalcitonin is rather a diagnostic tool able to guide
decisions on antibiotic therapy [22,36].
Two main mechanisms might be responsible for the increase
of circulating proADM in infections, including CAP. Firstly, as
a member of the calcitonin gene family, ADM is widely
expressed and extensively synthesized during severe infec-
tions, that is, sepsis, similar to other calcitonin peptides,
namely procalcitonin and calcitonin-gene related peptides
[37]. Our data demonstrate that proADM levels are also
increased in milder forms of infection like pneumonia, which
can be regarded as a precursor of sepsis. Bacterial endotoxins
and proinflammatory cytokines up-regulate ADM gene expres-
sion in many tissues, both in vitro and in vivo in rodents and
humans [38,39]. In addition, a decreased clearance by the kid-
neys may be responsible in part for the increased proADM lev-
els in infections [8]. This hypothesis is also supported by a
significant correlation between proADM and creatinine levels
in patients enrolled in our study. An alternative site of clear-
ance of proADM may be the lung. It has been reported that
ADM concentrations from the aorta are slightly lower than
those from the pulmonary artery during selective catheter sam-
pling [40]. Therefore, impaired removal of circulating ADM dur-
ing pulmonary circulation resulting from infection-associated
lung injury may partly contribute to the elevation of plasma
ADM levels [12].
Circulating levels of the potent mediator ADM are kept within
a very narrow range in order to prevent harmful excessive
effects. Hence, even in sepsis, circulating levels of ADM areAvailable online http://ccforum.com/content/10/3/R96
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only modestly elevated, and are not significantly different
between patients with systemic inflammatory response syn-
drome and patients with sepsis, prohibiting its use as a diag-
nostic and prognostic tool. In contrast, circulating levels of
less active precursor peptides are less tightly controlled and,
therefore, have a much higher diagnostic and prognostic
range. Our finding of an ADM precursor facilitates the assess-
ment of the actual release of ADM gene products under path-
ological conditions and thereby improves the diagnostic and
prognostic accuracy.
Some limitations of our study merit consideration. First,
proADM measurements were done as a predefined secondary
endpoint [22]. Future intervention studies should be encour-
aged to evaluate proADM levels as a prognostic tool in CAP
and other infections. Second, since the etiology remained uni-
dentified in a considerable proportion of cases because of the
low sensitivity of conventional microbiological tests, we cannot
make any conclusion about the usefulness of proADM to pre-
dict the etiology of CAP.
A single biomarker will always oversimplify the interpretation of
important variables and, therefore, proADM is meant to com-
plement, rather than to supersede, clinician's judgment and/or
validated severity scores. Besides clinical judgment, social
factors and patient preferences will also influence where and
how to manage CAP.
Conclusion
ProADM is a novel biomarker that seems to be a useful tool for
the risk stratification of patients with CAP. Accurate and
objective models of prognosis for CAP will help physicians to
assess a patient's risk profile and improve the decisions about
hospitalization and treatment.
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